Shield Therapeutics welcomes Fabiana Lacerca-Allen and Anders Lundstrom to its Board as Independent Directors

– UK, London –  Shield Therapeutics plc (LON: STX), a commercial-stage, pharmaceutical company with an initial focus on addressing iron deficiency, today announced the appointment of Fabiana Lacerca-Allen and Anders Lundstrom to its Board as Independent Non-Executive Directors with immediate effect.

“I am delighted to welcome both Fabiana and Anders to the Board of Shield. Fabiana’s extensive experience and knowledge of the pharmaceutical industry and her US compliance experience along with Anders’ extensive experience and knowledge of the pharmaceutical industry and his US commercialisation experience will significantly strengthen the current Board structure whilst Shield prepares for the US launch of Accrufer.” said Board Chairman, Hans Peter Hasler.

Mrs. Lacerca-Allen will become a member of the Group’s Audit Committee while Mr. Lundstrom will join the Remuneration Committee.

 About Fabiana Lacerca-Allen

Mrs Lacerca-Allen is currently SVP, Chief Compliance Officer at Aimmune Therapeutics based in San Francisco, California. She brings to Shield extensive experience in compliance having started and implemented compliance programs at several major pharmaceutical companies including Merck, Sharp & Dohme, Bristol-Myers Squibb Company, Mylan Laboratories, and Elan Pharmaceuticals.

Mrs. Lacerca-Allen was also a non-executive director at ArthroCare Corporation, a publicly traded company in the medical device sector before its acquisition by Smith & Nephew in 2014.

Fabiana holds a master’s in law from the University of California, a Doctor in Law, and a Bachelor in Law from the Universidad de Buenos Aires and is the recipient of several international recognitions and has been published extensively in areas of leadership and compliance.

About Anders Lundstrom

Mr Lundstrom is currently EVP and Chief Commercial Officer at Banner Life Sciences where he is planning and executing a US launch of a novel fumerate, Bafiertam, for the treatment of Multiple Sclerosis. He has over 25 years of experience in the pharmaceutical industry and has held senior commercial roles in AstraZeneca, Biogen, Orexo AB, where he was President and CEO from 2011 to 2013, and EMD Serono.

About Shield

Shield is a commercial-stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru /Accrufer, a novel, stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia.

Shield’s lead product, Feraccru/Accrufer, has been approved for use in the United States, European Union, UK, and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer in the US during 2021 through a highly experienced sales and marketing team. Feraccru is already being commercialized in the UK and European Union by Norgine B.V., who also have marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Feraccru/Accrufer in China, Hong Kong, Macau, and Taiwan.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.